Financing led by Novo Holdings, OrbiMed, and F-Prime Capital, with participation by new and current investors

融资由Novo Holdings、OrbiMed和F-Prime Capital牵头，新投资者和现有投资者参与

Proceeds to advance CUSP06, the company's antibody drug conjugate (ADC) targeting CDH6, to clinical proof-of-concept

继续将该公司针对CDH6的抗体-药物偶联物（ADC）CUSP06推进临床概念验证

NEW YORK, Jan. 4, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc., a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced an oversubscribed $100 million Series A financing round.

纽约，2024年1月4日/PRNewswire/-OnCusp Therapeutics，Inc.，一家致力于将尖端临床前创新转化为全球癌症患者临床验证治疗的生物制药公司，今天宣布超额认购1亿美元的a轮融资。

The round was co-led by Novo Holdings, OrbiMed, and F-Prime Capital, alongside Sofinnova Investments, Catalio Capital Management, Marshall Wace, Forge Life Science Partners, Blackbird BioVentures, CJNV BioVenture and others, as well as BioTrack Capital, a co-lead for the Seed Round. OnCusp Therapeutics has raised $139 million since its establishment in April 2021.

这一轮由Novo Holdings、OrbiMed和F-Prime Capital联合领导，还有Sofinnova Investments、Catalio Capital Management、Marshall Wace、Forge Life Science Partners、Blackbird BioVentures、CJNV BioVenture等，以及BioTrack Capital，种子轮的联合领导。OnCusp Therapeutics自2021年4月成立以来已筹集了1.39亿美元。

The proceeds from this financing will be used to advance CUSP06, an ADC targeting CDH6, toward clinical proof-of-concept. Additionally, the capital will aid in expanding the OnCusp portfolio and team..

这笔融资的收益将用于推动针对CDH6的ADC CUSP06进行临床概念验证。此外，资金将有助于扩大OnCusp投资组合和团队。。

CUSP06 has strong preclinical data demonstrating the potential for best-in-class activity. Engineered to increase potency, heighten 'bystander effect,' elevate linker stability, and overcome drug resistance, CUSP06's differentiating attributes could translate into higher clinical response rates and durability, with an improved safety profile.

CUSP06具有强大的临床前数据，证明了最佳活动的潜力。CUSP06旨在提高效力，增强“旁观者效应”，提高接头稳定性并克服耐药性，其独特的属性可以转化为更高的临床反应率和耐久性，并具有更好的安全性。

Having obtained FDA IND clearance in 3Q 2023, CUSP06 will be in a first-in-human Phase I study in the US..

CUSP06于2023年第3季度获得FDA IND许可，将在美国进行首次人体I期研究。。

'We are grateful to have the trust and support from some of the most prominent global biotech investors,' said Dr. Bing Yuan, Co-Founder and CEO of OnCusp Therapeutics. 'I am also thankful to the OnCusp team for their commitment and excellent work. We hold a strong conviction to develop innovative oncology therapies for patients.

OnCusp Therapeutics联合创始人兼首席执行官袁冰博士说，我们非常感谢一些最著名的全球生物技术投资者的信任和支持我也感谢OnCusp团队的承诺和出色的工作。我们坚信为患者开发创新的肿瘤疗法。

This significant Series A financing enables OnCusp to accelerate the development of CUSP06 and other game-changing therapeutics in our fight against cancer.' .

这一重要的A系列融资使OnCusp能够在我们对抗癌症的斗争中加速CUSP06和其他改变游戏规则的疗法的发展。”。

As part of the financing, OnCusp Therapeutics will appoint Dr. Karen Hong, Partner in the Venture Investments team at Novo Holdings US, Inc., a wholly owned subsidiary of Novo Holdings; Diyong Xu, Principal at OrbiMed; and Dr. Chong Xu, Partner at F-Prime Capital, to the company's Board of Directors..

作为融资的一部分，OnCusp Therapeutics将任命Karen Hong博士为Novo Holdings US，Inc.风险投资团队的合伙人，Novo Holdings US，Inc.是Novo Holdings的全资子公司；OrbiMed校长Diyong Xu；以及F-Prime Capital合伙人Chong Xu博士加入公司董事会。。

'We are thrilled to have co-led this round. The remarkable progress that the company has made in such a short time is a testament to its highly efficient business model and the team's exceptional execution capabilities,' said Dr. Karen Hong. 'We share OnCusp's mission in bringing oncology innovations to life and are committed to supporting the company's continued growth and success.'.

“我们很高兴能共同领导这一轮。凯伦·洪（KarenHong）博士说，公司在如此短的时间内取得的显著进步证明了其高效的商业模式和团队出色的执行能力我们与OnCusp共同致力于将肿瘤学创新带入生活，并致力于支持公司的持续增长和成功。”。

'ADCs have become one of the most promising modalities for treating cancer, and CDH6 is emerging as a winning ADC target. We believe CUSP06 is well positioned to unlock the full potential of this target, both in high and low CDH6 expressing tumors,' said Diyong Xu. 'We also look forward to OnCusp expanding its portfolio to fully leverage its translational and clinical development expertise.'.

“ADC已成为治疗癌症最有希望的方式之一，CDH6正在成为一个成功的ADC目标。徐迪勇（Diyong Xu）说，我们相信CUSP06在高CDH6表达和低CDH6表达的肿瘤中都能充分发挥这一靶点的潜力我们还期待OnCusp扩大其投资组合，以充分利用其转化和临床开发专业知识。”。

'I am excited to join the OnCusp Board at this transformative moment for the company,' stated Dr. Chong Xu. 'F-Prime is committed to proactively champion breakthrough approaches like CUSP06, which holds immense potential to help patients with ovarian cancer and other advanced solid tumors. I look forward to working with other board members and the executive team to propel OnCusp to its next phase of growth.'.

徐冲博士表示，在公司的这一变革时刻，我很高兴加入OnCusp董事会F-Prime致力于积极倡导CUSP06等突破性方法，CUSP06在帮助卵巢癌和其他晚期实体瘤患者方面具有巨大潜力。我期待着与其他董事会成员和执行团队合作，推动OnCusp进入下一个增长阶段。”。

'As a major investor since the company's inception, I am impressed by the entrepreneurship, commitment, and perseverance exemplified by the OnCusp team in the current challenging biotech market.' added Dr. Jiacong Guo, one of OnCusp's current Board Directors and a Principal at BioTrack Capital. 'I believe companies who are leading their field will emerge triumphant in their mission.

“作为公司成立以来的主要投资者，我对OnCusp团队在当前充满挑战的生物技术市场中表现出的创业精神、承诺和毅力印象深刻。”OnCusp现任董事之一、BioTrack Capital负责人郭家聪博士补充道我相信，在其领域处于领先地位的公司将在其使命中取得胜利。

I am confident that OnCusp is one of those companies.'.

我相信OnCusp就是其中之一。”。

About OnCusp Therapeutics

关于OnCusp Therapeutics

OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical and clinical programs, and creating value through global partnerships.

OnCusp Therapeutics，Inc.，总部位于纽约市，是一家生物制药公司，致力于将尖端的临床前创新转化为全球癌症患者的临床验证治疗。OnCusp由袁冰博士、埃里克·斯洛斯伯格博士和安迪·福博士共同创立，建立了一支强大的老兵团队，他们在建立初创生物技术公司、领导成功的临床前和临床项目以及通过全球伙伴关系创造价值方面有着良好的业绩记录。

The company is committed to accelerating the advancement of globally competitive oncology assets for patients. .

该公司致力于加速为患者提供具有全球竞争力的肿瘤学资产。。

About CUSP06

关于CUSP06

CUSP06, a CDH6 ADC, is composed of a proprietary antibody with high CDH6 binding affinity, a protease-cleavable linker, and an exatecan payload (a potent and clinically validated topoisomerase-1 inhibitor). The linker is designed to complement the exatecan payload, enabling a highly stable and homogenous ADC.

CUSP06是一种CDH6 ADC，由具有高CDH6结合亲和力的专有抗体，蛋白酶可切割接头和exatecan有效载荷（一种有效且经临床验证的拓扑异构酶-1抑制剂）组成。该连接器旨在补充exatecan有效载荷，从而实现高度稳定和同质的ADC。

The payload is a weak substrate for BCRP/P-gp, which are drug efflux pumps that drive chemoresistance to many therapies. In preclinical data, this linker-payload has been shown to have an increased 'bystander effect' compared to competitor ADCs. CUSP06 has a drug-to-antibody ratio of eight. OnCusp obtained the exclusive global rights (outside of China) to lead the development and commercialization of CUSP06 from Multitude Therapeutics.

有效载荷是BCRP/P-gp的弱底物，BCRP/P-gp是驱动对许多疗法的化学抗性的药物外排泵。在临床前数据中，与竞争对手ADC相比，这种连接器有效载荷已被证明具有增加的“旁观者效应”。CUSP06的药物抗体比为8。OnCusp获得了（中国境外）独家全球权利，以领导Multiple Therapeutics的CUSP06开发和商业化。

WuXi XDC, a global CRDMO company dedicated to end-to-end bioconjugates services, is the CMC partner for CUSP06..

无锡XDC是一家致力于端到端生物共轭服务的全球CRDMO公司，是CUSP06的CMC合作伙伴。。

CONTACT: zhuli huang, [email protected]

联系人：zhuli huang，[受电子邮件保护]

SOURCE OnCusp Therapeutics

来源OnCusp Therapeutics